Literature DB >> 20536731

Involvement of endotoxin in the mortality of mice with gut-derived sepsis due to methicillin-resistant Staphylococcus aureus.

Masashi Uramatsu1, Tetsuya Matsumoto, Kazuhiro Tateda, Kazutoshi Shibuya, Shuichi Miyazaki, Tetsuya Horino, Masaaki Tanabe, Yoshinobu Sumiyama, Shinya Kusachi, Keizo Yamaguchi.   

Abstract

MRSA causes a wide diversity of diseases, ranging from benign skin infections to life-threatening diseases, such as sepsis. However, there have been few reports of the pathophysiology and mechanisms of sepsis resulting from the gut-derived origin of MRSA. Therefore, we established a murine model of gut-derived sepsis with MRSA and factors of MRSA sepsis that cause deterioration. We separated mice into four groups according to antibiotic treatment as follows: (i) ABPC 40 mg/kg; (ii) CAZ 80 mg/kg; (iii) CAZ 80 mg/kg + endotoxin 10 microg/mouse; and (iv) saline-treated control groups. Gut-derived sepsis was induced by i.p. injection of cyclophosphamide after colonization of MRSA strain 334 in the intestine. After the induction of sepsis, significantly more CAZ-treated mice survived compared with ABPC-treated and control groups. MRSA were detected in the blood and liver among all groups. Endotoxin levels were significantly lower in the CAZ-treated group compared to other groups. Inflammatory cytokine levels in the serum were lower in the CAZ-treated group compared to other groups. Fecal culture showed a lower level of colonization of E. coli in the CAZ-treated group compared to other groups. In conclusion, we found that CAZ-treatment ameliorates infection and suppresses endotoxin level by the elimination of E. coli from the intestinal tract of mice. However, giving endotoxin in the CAZ-treated group increased mortality to almost the same level as in the ABPC-treated group. These results suggest endotoxin released from resident E. coli in the intestine is involved in clinical deterioration resulting from gut-derived MRSA sepsis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536731     DOI: 10.1111/j.1348-0421.2010.00217.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  6 in total

1.  Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling.

Authors:  Mallappa Anitha; Matam Vijay-Kumar; Shanthi V Sitaraman; Andrew T Gewirtz; Shanthi Srinivasan
Journal:  Gastroenterology       Date:  2012-06-23       Impact factor: 22.682

2.  Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility.

Authors:  Paul Andrew Muller; Balázs Koscsó; Gaurav Manohar Rajani; Korey Stevanovic; Marie-Luise Berres; Daigo Hashimoto; Arthur Mortha; Marylene Leboeuf; Xiu-Min Li; Daniel Mucida; E Richard Stanley; Stephanie Dahan; Kara Gross Margolis; Michael David Gershon; Miriam Merad; Milena Bogunovic
Journal:  Cell       Date:  2014-07-17       Impact factor: 41.582

3.  Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle.

Authors:  Ijaz Ahmad; Haihong Hao; Lingli Huang; Pascal Sanders; Xu Wang; Dongmei Chen; Yanfei Tao; Shuyu Xie; Kuang Xiuhua; Juan Li; Wan Dan; Zonghui Yuan
Journal:  Front Microbiol       Date:  2015-06-17       Impact factor: 5.640

4.  A mouse model of Staphylococcus aureus small intestinal infection.

Authors:  Sarah Larcombe; Jhih-Hang Jiang; Melanie L Hutton; Helen E Abud; Anton Y Peleg; Dena Lyras
Journal:  J Med Microbiol       Date:  2020-01-31       Impact factor: 2.472

5.  Ginsenoside Rb1 attenuates intestinal ischemia/reperfusion‑induced inflammation and oxidative stress via activation of the PI3K/Akt/Nrf2 signaling pathway.

Authors:  Sufang Chen; Xiang Li; Yanling Wang; Panwei Mu; Chaojin Chen; Pinjie Huang; Dezhao Liu
Journal:  Mol Med Rep       Date:  2019-03-12       Impact factor: 2.952

6.  The gut is the epicentre of antibiotic resistance.

Authors:  Jean Carlet
Journal:  Antimicrob Resist Infect Control       Date:  2012-11-27       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.